Proxsys Rx
OCTOBER 6, 2022
That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.
Pharmaceutical Technology
FEBRUARY 7, 2023
An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Overall, it is never too soon to begin market access activities, but it can easily be too late.
Expert insights. Personalized for you.
52 
Let's personalize your content